Amylin: A Hormone Therapy Moving Beyond Insulin

Amylin is a hormone naturally produced in the pancreas that works alongside insulin to help regulate blood sugar levels. Scientists first identified amylin in 1986, but for years its potential as a therapy went largely unexplored. It wasn't until the early 2000s—nearly 20 years later—that researchers developed pramlintide, a human-made version of amylin designed to mimic the hormone's effects.

Pramlintide became the first amylin-based medication approved by regulatory agencies for use in Type 1 and Type 2 diabetes. It is used as an adjunct therapy, meaning it works alongside insulin therapy rather than replacing it. The drug was designed to help people using insulin achieve better blood sugar control by helping their bodies manage the timing and absorption of glucose.

For many years after pramlintide's approval, amylin's therapeutic potential remained largely underexplored. Recent research has changed that picture. Scientists are discovering that amylin affects multiple organ systems in the body, not just blood sugar regulation. This broader understanding has sparked renewed interest in developing new amylin-based therapies.

Researchers are now advancing several new amylin-based treatments toward clinical testing. A particularly promising direction is combining amylin with additional molecules to create combination therapies. These experimental treatments are being studied for people with diabetes and obesity, reflecting growing recognition that amylin may play a role in managing multiple metabolic conditions.

As this research continues, amylin represents one of several therapeutic pathways being explored to improve outcomes for people living with diabetes and related cardiometabolic diseases.

Source: Nature metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.